Molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGF receptor-mutated non-small-cell lung cancer: A narrative review
| Autor: | Xuewen Wang, Hao Liu, Bing Chen, Kangping Huang, Hong Yao, Zhengjun Huang, Dafen Xu, Xinhua Lin, Zhijun Li |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Drug Lung Neoplasms media_common.quotation_subject medicine.disease_cause 03 medical and health sciences T790M 0302 clinical medicine Pharmacokinetics Carcinoma Non-Small-Cell Lung medicine Humans Lung cancer Receptor Protein Kinase Inhibitors media_common Pharmacology chemistry.chemical_classification Flavonoids Mutation business.industry Biflavonoid medicine.disease respiratory tract diseases ErbB Receptors 030104 developmental biology chemistry Drug Resistance Neoplasm Cancer research Efflux business 030217 neurology & neurosurgery |
| Zdroj: | British journal of pharmacologyREFERENCES. 178(6) |
| ISSN: | 1476-5381 |
| Popis: | Here, we review the molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGF receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) and particularly the possible mechanism(s) of delicaflavone, a biflavonoid extracted from Selaginella doederleinii Hieron. EGFR TK inhibitors (EGFR-TKI) are ubiquitously used in the treatment of NSCLC bearing EGFR mutations. However, patients treated with EGFR-TKI inevitably and continuously develop resistance. In laboratory studies, flavonoids, as potential adjuvants for cancer chemotherapy, exhibited anti-cancer properties such as inhibition of chemoresistance by interference with ABC transporters-induced drug efflux, curbing of c-MET amplification, or reversal of T790M mutation-mediated resistance. The current review aims at summarizing the association between the anti-cancer potentials of flavonoids and their possible regulatory roles in certain types of mutation that could trigger EGFR-TKI resistance in NSCLC. Potential practical applications of these phytochemicals, as well as the relevant pharmacokinetics, are also discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text